title: Long-term clinical experience with darunavir (2007-2015) in a large cohort of HIV-infected patients in Spain.
abstract: The clinical experience with the protease inhibitor darunavir/ritonavir (DRV/r) was retrospectively evaluated in a cohort of 173 HIV+ patients who initiated antiretroviral treatment including DRV/r (period 2007-2015). The 43.2% had a CD4 nadir ≤100 cells/mm3, 64.1% were treatment-experienced, and 36.5% had failed to >3 lines of antiretroviral therapy. Nonetheless, the rate of virological suppression (HIV-RNA <50 copies/ml) in naïve patients was 63%, 66.7%, and 63.6% at 48, 96, and 144 weeks, respectively. The rate of virological suppression in treatment-experienced patients was 62.7%, 78.7%, and 79.1% at 48, 96, and 144 weeks, respectively. No differences were observed according to the immunovirological status neither dosage of DRV/r. Most of them (82.6%) maintained DRV/r treatment. Causes for DRV/r discontinuation were mainly gastrointestinal and cutaneous adverse events (10.5%), switch to simplification treatment strategies (3.5%) and virological failure (1.7%). These findings demonstrate the prolonged efficacy and tolerability of DRV/r even in multi-treated HIV+ patients with an unfavorable immunovirological status. J. Med. Virol. 88:2125-2131, 2016. © 2016 Wiley Periodicals, Inc.
authors.affiliation: Division of Clinical Virology, Instituto de Investigación Biomédica de A Coruña (INIBIC)-Complejo Hospitalario Universitario de A Coruña (CHUAC), SERGAS, Universidad de A Coruña, A Coruña, Spain.
authors.forename: Berta
authors.initials: B
authors.lastname: Pernas
authors.affiliation: Division of Clinical Virology, Instituto de Investigación Biomédica de A Coruña (INIBIC)-Complejo Hospitalario Universitario de A Coruña (CHUAC), SERGAS, Universidad de A Coruña, A Coruña, Spain.
authors.forename: Marta
authors.initials: M
authors.lastname: Grandal
authors.affiliation: Division of Clinical Virology, Instituto de Investigación Biomédica de A Coruña (INIBIC)-Complejo Hospitalario Universitario de A Coruña (CHUAC), SERGAS, Universidad de A Coruña, A Coruña, Spain.
authors.forename: Andrés
authors.initials: A
authors.lastname: Tabernilla
authors.affiliation: Service of Pharmacy, Complejo Hospitalario Universitario de A Coruña, SERGAS, A Coruña, Spain.
authors.forename: Purificación
authors.initials: P
authors.lastname: Cid
authors.affiliation: Clinical Epidemiology and Biostatistics Unit, Instituto de Investigación Biomédica de A Coruña (INIBIC)-Complejo Hospitalario Universitario de A Coruña, SERGAS, A Coruña, Spain.
authors.forename: Sonia
authors.initials: S
authors.lastname: Pértega
authors.affiliation: Division of Clinical Virology, Instituto de Investigación Biomédica de A Coruña (INIBIC)-Complejo Hospitalario Universitario de A Coruña (CHUAC), SERGAS, Universidad de A Coruña, A Coruña, Spain.
authors.forename: Ángeles
authors.initials: Á
authors.lastname: Castro-Iglesias
authors.affiliation: Division of Clinical Virology, Instituto de Investigación Biomédica de A Coruña (INIBIC)-Complejo Hospitalario Universitario de A Coruña (CHUAC), SERGAS, Universidad de A Coruña, A Coruña, Spain.
authors.forename: Álvaro
authors.initials: Á
authors.lastname: Mena
authors.affiliation: Service of Pharmacy, Complejo Hospitalario Universitario de A Coruña, SERGAS, A Coruña, Spain.
authors.forename: Luis
authors.initials: L
authors.lastname: Margusino
authors.affiliation: Division of Clinical Virology, Instituto de Investigación Biomédica de A Coruña (INIBIC)-Complejo Hospitalario Universitario de A Coruña (CHUAC), SERGAS, Universidad de A Coruña, A Coruña, Spain.
authors.forename: José D
authors.initials: JD
authors.lastname: Pedreira
authors.affiliation: Division of Clinical Virology, Instituto de Investigación Biomédica de A Coruña (INIBIC)-Complejo Hospitalario Universitario de A Coruña (CHUAC), SERGAS, Universidad de A Coruña, A Coruña, Spain. eva.poveda.lopez@sergas.es.
authors.forename: Eva
authors.initials: E
authors.lastname: Poveda
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D018791:CD4 Lymphocyte Count; D000069454:Darunavir / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000453:epidemiology / Q000821:virology; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D015497:HIV-1 / Q000187:drug effects* / Q000235:genetics; D006801:Humans; D000069451:Long Term Adverse Effects; D061466:Lopinavir / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D012367:RNA, Viral / Q000097:blood; D012189:Retrospective Studies; D019438:Ritonavir / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D013030:Spain; D013449:Sulfonamides / Q000009:adverse effects / Q000627:therapeutic use; D019562:Viral Load / Q000187:drug effects*; D055815:Young Adult
chemical_list: D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D012367:RNA, Viral; D013449:Sulfonamides; D061466:Lopinavir; D019438:Ritonavir; D000069454:Darunavir
keywords: HIV infection; darunavir; efficacy; safety